Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edoxaban for prevention of catheter-related thrombosis in cancer patients
NCT06149533Phase 3Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Nov 2023
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of edoxaban in catheter-related thrombosis (CRT), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Planned start Nov 2023; status: not yet recruiting.
02
Drugs
edoxaban
03
Conditions
catheter-related thrombosis (CRT)
Beyond the preview
Go deeper on NCT06149533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06149533.